Guardant Health Inc (NAS:GH)
$ 29.54 0 (0%) Market Cap: 3.61 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 52.66 GF Score: 70/100

Guardant Health Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 09, 2021 / 08:15PM GMT
Release Date Price: $130.85 (+0.65%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Everyone, thanks for joining us on the first day of our Healthcare conference. I'm Tejas Savant, and I cover the Life Science Tools and Diagnostics Sector here at Morgan Stanley. Delighted to have Guardant join us today. And representing the company, we have Helmy Eltoukhy and AmirAli Talasaz, Co-CEOs; and Mike Bell, CFO. So welcome, gents.

Before we get started, just some important disclosures here. Please see the Morgan Stanley Research Disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales rep.

Questions & Answers

Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

So maybe just to get started, it's been over 3 years, Helmy and AmirAli, since Guardant went public in the fall of 2018 and even longer since you launched G360. What has surprised you the most on the upside and on the downside as you've sought to commercialize liquid biopsy, first in therapy and now, of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot